Gold prices hit 2-week high as Trump-Fed feud escalates with Cook firing
On Friday, Goldman Sachs reiterated its Buy rating on Ultragenyx Pharmaceutical (TADAWUL:2070) Inc. (NASDAQ:RARE) shares with a steady price target of $78.00. The firm's analyst highlighted Ultragenyx's fourth-quarter total revenue of $164.9 million, aligning with the pre-announcement in January and surpassing Goldman Sachs and Visible Alpha Consensus estimates of $159.7 million and $144.2 million, respectively. According to InvestingPro data, the company has demonstrated strong revenue growth of 27.44% over the last twelve months, while maintaining a healthy liquidity position with a current ratio of 2.81. Sales from Crysvita and Dojolvi were reported at $115.2 million and $31.1 million, consistent with the pre-announcement figures and compared to Goldman Sachs and Visible Alpha projections of $111.2 million/$97.6 million and $30 million/$24.5 million, respectively.
Ultragenyx has reiterated its full-year 2025 revenue guidance, which is projected to be between $640 million and $670 million. This guidance compares to the new estimates from Goldman Sachs and Visible Alpha, which are $654 million and $637 million, respectively. InvestingPro analysis reveals that 3 analysts have revised their earnings upwards for the upcoming period, though the company is not expected to be profitable this year. For detailed financial analysis and 7 additional ProTips, subscribers can access the comprehensive Pro Research Report. The company's earnings call was dominated by discussions on the Phase 3 Orbit study of setrusumab for treating osteogenesis imperfecta. The management expressed confidence in the study's success, referencing the Phase 2 results that showed a 67% reduction in annualized fracture rates at 14 months, with a p-value of 0.0014. With analyst targets ranging from $47 to $140 and InvestingPro's Fair Value analysis suggesting the stock is slightly undervalued, investors seeking deeper insights can access the full financial health assessment and valuation metrics through InvestingPro's comprehensive research tools.
The analyst from Goldman Sachs also pointed to the potential for further upside from Ultragenyx's pipeline. This includes the anticipated PDUFA decision and the potential commercial launch of the gene therapy UX111 for Sanfilippo syndrome, which is expected in the second half of 2025. Additionally, the Biologics License Application (BLA) filing for gene therapy DTX401 in GSD1a is anticipated by mid-2025. The analyst's note concluded with a positive outlook on the clinical and commercial prospects for setrusumab in osteogenesis imperfecta, among other pipeline developments.
In other recent news, Ultragenyx Pharmaceutical Inc. has been the subject of several analyst notes, all maintaining positive ratings. Truist Securities upheld a Buy rating, with a $140 price target, applauding the company's Q4 2024 total revenue of $164.9 million and projecting a significant revenue increase for 2025. The firm also highlighted the company's path to profitability by 2027, largely due to the ongoing Phase 3 OBRIT study, which is expected to have an interim analysis in mid-2025.
In addition, Goldman Sachs reaffirmed a Buy rating, noting Ultragenyx's FY 2024 revenue forecast, which surpasses previous estimates, and the company's FY 2025 revenue guidance, indicating a growth of 14-20%. Goldman Sachs also expressed confidence in the Phase 3 Orbit study of setrusumab for osteogenesis imperfecta.
RBC Capital Markets reiterated an Outperform rating, expressing optimism about the company's drug for Osteogenesis Imperfecta, while H.C. Wainwright maintained its Buy rating, in light of the commencement of the pivotal Phase 3 Aspire study for GTX-102, an experimental treatment for Angelman syndrome.
Ultragenyx also reported positive data on its experimental gene therapy, UX111, for Sanfilippo syndrome type A, showing significant cognitive improvements in patients. The results will be part of a Biologics License Application submitted to the FDA, with a decision expected in the second half of 2025. These are the latest developments in Ultragenyx's ongoing efforts to develop therapies for rare and ultra-rare genetic diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.